CANBRIDGE PHARM.DL-00001 Market Cap ($108.75 Million)
Market Cap & Net Worth: CANBRIDGE PHARM.DL-00001 (MF1)
CANBRIDGE PHARM.DL-00001 market cap. CANBRIDGE PHARM.DL-00001 (F:MF1) has a market capitalization of $108.75 Million (€93.02 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #18690 globally and #1729 in its home market, demonstrating a -4.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CANBRIDGE PHARM.DL-00001's stock price €0.18 by its total outstanding shares 511120234 (511.12 Million). Also see CANBRIDGE PHARM.DL-00001 (MF1) cash conversion ratio for how efficiently the company converts equity into cash flow.
CANBRIDGE PHARM.DL-00001 Market Cap History (2022–2026)
CANBRIDGE PHARM.DL-00001 market cap history from 2022 to 2026. Data shows change from $152.97 Million to $108.75 Million (-15.40% CAGR). Check MF1 live share price for real-time trading data and today's change.
CANBRIDGE PHARM.DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CANBRIDGE PHARM.DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CANBRIDGE PHARM.DL-00001 (MF1) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.30x
CANBRIDGE PHARM.DL-00001's market cap is 2.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.74x
CANBRIDGE PHARM.DL-00001's market cap is 7.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $152.97 Million | $78.97 Million | -$483.48 Million | 1.94x | N/A |
| 2023 | $65.13 Million | $102.87 Million | -$378.84 Million | 0.63x | N/A |
| 2024 | $7.77 Million | $85.10 Million | -$442.62 Million | 0.09x | N/A |
| 2025 | $114.73 Million | $49.98 Million | $14.82 Million | 2.30x | 7.74x |
Competitor Companies of MF1 by Market Capitalization
Companies near CANBRIDGE PHARM.DL-00001 in the global market cap rankings as of November 4, 2026. Also see CANBRIDGE PHARM.DL-00001 balance sheet assets for a full breakdown of the balance sheet.
Key companies related to CANBRIDGE PHARM.DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of CANBRIDGE PHARM.DL-00001 (2022–2026)
Market capitalization of CANBRIDGE PHARM.DL-00001 from 2022 to today. Between 2022 and today, CANBRIDGE PHARM.DL-00001's market cap moved from $152.97 Million to $ 108.75 Million, with a yearly change of -15.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €108.75 Million | -5.21% |
| 2025 | €114.73 Million | +1376.92% |
| 2024 | €7.77 Million | -88.07% |
| 2023 | €65.13 Million | -57.42% |
| 2022 | €152.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of CANBRIDGE PHARM.DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.75 Million USD |
| MoneyControl | $108.75 Million USD |
| MarketWatch | $108.75 Million USD |
| marketcap.company | $108.75 Million USD |
| Reuters | $108.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more